XML 51 R35.htm IDEA: XBRL DOCUMENT
v3.22.4

Shareholders' Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Equity [Abstract] |
Schedule of Balance Of Non-controlling Interests | The changes in the balance of our four non-controlling interests for 2022, 2021 and 2020 are as follows (in thousands):
| RPSFT |  | Legacy Investors Partnerships |  | Continuing Investors Partnerships (1) |  | EPA Holdings |  | Total
December 31, 2019 | $ | 35,883 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 35,883 |
Contributions | — |  |  | 1,165,258 |  |  | 9,418 |  |  | — |  |  | 1,174,676 |
Transfer of interests | — |  |  | 1,037,161 |  |  | — |  |  | — |  |  | 1,037,161 |
Distributions | (112,339) |  |  | (594,592) |  |  | (85,426) |  |  | — |  |  | (792,357) |
Net income prior to IPO | 42,151 |  |  | 102,892 |  |  | — |  |  | — |  |  | 145,043 |
Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity | — |  |  | (750) |  |  | 2,433,848 |  |  | — |  |  | 2,433,098 |
Issuance of Class A ordinary shares sold in IPO, net of offering costs | — |  |  | — |  |  | 758,354 |  |  | — |  |  | 758,354 |
Other exchanges | — |  |  | — |  |  | (309,566) |  |  | — |  |  | (309,566) |
Net income subsequent to IPO | 46,741 |  |  | 218,137 |  |  | 316,993 |  |  | — |  |  | 581,871 |
Other comprehensive income/(loss): |  |  |  |  |  |  |  |  |
Unrealized gains on available for sale debt securities | — |  |  | 15,015 |  |  | 7,488 |  |  | — |  |  | 22,503 |
Reclassification of unrealized gains on available for sale debt securities | — |  |  | (3,612) |  |  | (6,018) |  |  | — |  |  | (9,630) |
December 31, 2020 | $ | 12,436 |  |  | $ | 1,939,509 |  |  | $ | 3,125,091 |  |  | $ | — |  |  | $ | 5,077,036 |
Contributions | — |  |  | 35,148 |  |  | 13,391 |  |  | — |  |  | 48,539 |
Distributions | (56,490) |  |  | (425,050) |  |  | (133,433) |  |  | — |  |  | (614,973) |
Other exchanges | — |  |  | — |  |  | (642,974) |  |  | — |  |  | (642,974) |
Net income | 57,582 |  |  | 266,570 |  |  | 297,321 |  |  | — |  |  | 621,473 |
Other comprehensive income/(loss): |  |  |  |  |  |  |  |  |
Unrealized gains on available for sale debt securities | — |  |  | 2,038 |  |  | 3,227 |  |  | — |  |  | 5,265 |
Reclassification of unrealized gains on available for sale debt securities | — |  |  | (8,946) |  |  | (13,469) |  |  | — |  |  | (22,415) |
December 31, 2021 | $ | 13,528 |  |  | $ | 1,809,269 |  |  | $ | 2,649,154 |  |  | $ | — |  |  | $ | 4,471,951 |
Contributions | — |  |  | 6,343 |  |  | 5,253 |  |  | — |  |  | 11,596 |
Distributions | (24,687) |  |  | (435,446) |  |  | (144,115) |  |  | — |  |  | (604,248) |
Other exchanges | — |  |  | — |  |  | (157,494) |  |  | — |  |  | (157,494) |
Net Income | 10,562 |  |  | 152,895 |  |  | 23,775 |  |  | — |  |  | 187,232 |
Other comprehensive income/(loss): |  |  |  |  |  |  |  |  |
Unrealized gains on available for sale debt securities | — |  |  | 4,218 |  |  | 5,520 |  |  | — |  |  | 9,738 |
Reclassification of unrealized gains on available for sale debt securities | — |  |  | (9,392) |  |  | (12,160) |  |  | — |  |  | (21,552) |
December 31, 2022 | $ | (597) |  |  | $ | 1,527,887 |  |  | $ | 2,369,933 |  |  | $ | — |  |  | $ | 3,897,223 |
(1)Related to the Continuing Investors Partnerships’ ownership of approximately 27%, 29% and 36% in RP Holdings through their ownership of RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively. Royalty Pharma plc owns the remaining and 73%, 71% and 64% of RP Holdings through its ownership of RP Holdings Class A Interests and RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration